Efficacy and Safety of Integrated Maxing Shigan Decoction and Azithromycin for Mycoplasma Pneumoniae Pneumonia in Children: A Systematic Review and Meta-Analysis

IF 2 4区 医学 Q3 PHARMACOLOGY & PHARMACY Journal of Clinical Pharmacy and Therapeutics Pub Date : 2023-02-04 DOI:10.1155/2023/2596562
Qiong Huang, Qiong Zhang, Si Li
{"title":"Efficacy and Safety of Integrated Maxing Shigan Decoction and Azithromycin for Mycoplasma Pneumoniae Pneumonia in Children: A Systematic Review and Meta-Analysis","authors":"Qiong Huang,&nbsp;Qiong Zhang,&nbsp;Si Li","doi":"10.1155/2023/2596562","DOIUrl":null,"url":null,"abstract":"<div>\n <p><i>Background</i>. The primary objective of this study was to thoroughly assess the effectiveness of treating pediatric mycoplasma pneumoniae pneumonia (MPP) with Maxing Shigan decoction (MSD) and azithromycin. <i>Materials and Methods</i>. We comprehensively reviewed the literature for randomized controlled trials research on MPP treated by MSD combined with azithromycin in children in the databases of Medicine, Embase, ClinicalTrials.gov, Cochrane Library, PubMed, CNKI, WangFang, and VIP from inception to April 2021. dds ratio (OR) was used for dichotomous data, while the mean difference (MD) was adopted for continuous variables as effect size, both of which were demonstrated in effect size and 95% confidence intervals (CI). <i>Results</i>. A total of 49 studies with 5704 patients were included in the meta-analysis. The results showed that MSD combined with azithromycin significantly improved the clinical efficacy (OR = 5.31, 95% CI: (4.35, 6.49), and <i>p</i>  &lt;  0.001) and reduced the chest X-rays recovery time (MD = −2.25, 95% CI: (−2.86, −1.65), and <i>p</i>  &lt;  0.001), cough duration (MD = −2.53, 95% CI: (−2.93. −2.12), and <i>p</i>  &lt;  0.001), CRP (MD = −7.84, 95% CI: (−9.51, −6.17), and <i>p</i>  &lt;  0.001), fever duration (MD = −1.53, 95% CI: (−1.78, −1.28), and <i>p</i>  &lt;  0.001), hospital days (MD = −2.70, 95% CI: (−3.35, −2.06), and <i>p</i>  &lt;  0.001), moist rales duration (MD = −2.00, 95% CI: (−2.33, −1.68), and <i>p</i>  &lt;  0.001), and adverse effects (OR = 0.55, 95% CI: (0.41, 0.75), and <i>p</i>  &lt;  0.001) when compared with azithromycin alone in the treatment of MPP in children. Meta-regression analysis demonstrated that the course of disease and duration of medication contribute to the heterogeneity across studies when comparing outcomes between groups. <i>Conclusion</i>. MSD and azithromycin worked better when used in conjunction to treat MPP in young patients. These findings require confirmation by additional high-quality, big sample RCTs.</p>\n </div>","PeriodicalId":15381,"journal":{"name":"Journal of Clinical Pharmacy and Therapeutics","volume":"2023 1","pages":""},"PeriodicalIF":2.0000,"publicationDate":"2023-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/2023/2596562","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Pharmacy and Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1155/2023/2596562","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background. The primary objective of this study was to thoroughly assess the effectiveness of treating pediatric mycoplasma pneumoniae pneumonia (MPP) with Maxing Shigan decoction (MSD) and azithromycin. Materials and Methods. We comprehensively reviewed the literature for randomized controlled trials research on MPP treated by MSD combined with azithromycin in children in the databases of Medicine, Embase, ClinicalTrials.gov, Cochrane Library, PubMed, CNKI, WangFang, and VIP from inception to April 2021. dds ratio (OR) was used for dichotomous data, while the mean difference (MD) was adopted for continuous variables as effect size, both of which were demonstrated in effect size and 95% confidence intervals (CI). Results. A total of 49 studies with 5704 patients were included in the meta-analysis. The results showed that MSD combined with azithromycin significantly improved the clinical efficacy (OR = 5.31, 95% CI: (4.35, 6.49), and p  <  0.001) and reduced the chest X-rays recovery time (MD = −2.25, 95% CI: (−2.86, −1.65), and p  <  0.001), cough duration (MD = −2.53, 95% CI: (−2.93. −2.12), and p  <  0.001), CRP (MD = −7.84, 95% CI: (−9.51, −6.17), and p  <  0.001), fever duration (MD = −1.53, 95% CI: (−1.78, −1.28), and p  <  0.001), hospital days (MD = −2.70, 95% CI: (−3.35, −2.06), and p  <  0.001), moist rales duration (MD = −2.00, 95% CI: (−2.33, −1.68), and p  <  0.001), and adverse effects (OR = 0.55, 95% CI: (0.41, 0.75), and p  <  0.001) when compared with azithromycin alone in the treatment of MPP in children. Meta-regression analysis demonstrated that the course of disease and duration of medication contribute to the heterogeneity across studies when comparing outcomes between groups. Conclusion. MSD and azithromycin worked better when used in conjunction to treat MPP in young patients. These findings require confirmation by additional high-quality, big sample RCTs.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
麻杏食肝汤联合阿奇霉素治疗儿童肺炎支原体肺炎的疗效和安全性:系统评价及Meta分析
背景本研究的主要目的是全面评价麻杏食肝汤(MSD)和阿奇霉素治疗小儿肺炎支原体肺炎(MPP)的疗效。材料和方法。我们从开始到2021年4月,在Medicine、Embase、ClinicalTrials.gov、Cochrane Library、PubMed、CNKI、WangFang和VIP数据库中,全面回顾了默沙东联合阿奇霉素治疗儿童MPP的随机对照试验研究文献。对于二分法数据,采用了dds比率(OR),而对于作为效应大小的连续变量,采用了平均差(MD),这两者都在效应大小和95%置信区间(CI)中得到了证明。后果荟萃分析共纳入49项研究,涉及5704名患者。结果表明,MSD与阿奇霉素联合用药可显著提高临床疗效(OR = 5.31,95%可信区间:(4.35,6.49),p  <   0.001),并减少了胸部X射线恢复时间(MD = −2.25,95%置信区间:(−2.86,−1.65),p  <   0.001),咳嗽持续时间(MD = −2.53,95%CI:(−2.93.−2.12)和p  <   0.001)、CRP(MD = −7.84,95%置信区间:(−9.51,−6.17),p  <   0.001)、发烧持续时间(MD = −1.53,95%置信区间:(−1.78,−1.28),p  <   0.001),住院天数(MD = −2.70,95%置信区间:(−3.35,−2.06),p  <   0.001),湿啰音持续时间(MD = −2.00,95%置信区间:(−2.33,−1.68),p  <   0.001)和不良反应(OR = 0.55,95%置信区间:(0.41,0.75),p  <   0.001)。荟萃回归分析表明,在比较各组之间的结果时,病程和用药时间会导致研究的异质性。结论MSD和阿奇霉素联合治疗年轻患者的MPP效果更好。这些发现需要额外的高质量、大样本随机对照试验来证实。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.10
自引率
5.00%
发文量
226
审稿时长
6 months
期刊介绍: The Journal of Clinical Pharmacy and Therapeutics provides a forum for clinicians, pharmacists and pharmacologists to explore and report on issues of common interest. Reports and commentaries on current issues in medical and pharmaceutical practice are encouraged. Papers on evidence-based clinical practice and multidisciplinary collaborative work are particularly welcome. Regular sections in the journal include: editorials, commentaries, reviews (including systematic overviews and meta-analyses), original research and reports, and book reviews. Its scope embraces all aspects of clinical drug development and therapeutics, including: Rational therapeutics Evidence-based practice Safety, cost-effectiveness and clinical efficacy of drugs Drug interactions Clinical impact of drug formulations Pharmacogenetics Personalised, stratified and translational medicine Clinical pharmacokinetics.
期刊最新文献
Therapeutics for Rheumatoid Arthritis: A Phase 4 Clinical Trial Analysis With a Focus on Disability Outcomes Concurrent Intravenous Drug Administration to the Critically Ill: Compatibility of Ginkgo Biloba Extract With Frequently Used Drugs in the Neurological Intensive Care Unit Population Pharmacokinetics of Tigecycline in Critically Ill Patients and Optimal Dosage Regimens With Dose Simulations Based on Infection Type and Renal Function Adherence to Methotrexate Safety Guidelines in Rheumatoid Arthritis: Real-World Evidence From South Africa’s Public Health System Correction to “Impaired Autophagic Flux by Citalopram Inhibits DR5 Degradation and Increases TRAIL-Mediated Apoptosis”
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1